Login / Signup

DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation.

Zhenchong XiongLin YangNing LiJianchang FuPeng LiuPeng SunWeidong WeiXiaoming Xie
Published in: Clinical and translational medicine (2022)
We revealed that DAB2IP attenuates chemoresistance of TNBC via inhibition of RAC1-mediated β-catenin nuclear accumulation. Decitabine treatment results in re-expression of DAB2IP by inhibiting DNA methylation and could be a potential therapeutic strategy for chemoresistance in TNBC.
Keyphrases